Stroke-MRI: Extending the Time-Window: Recent Trials and Clinical Practice

Hacke W Donnan G Fieschi C . ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768–74.

Hjort N Butcher K Davis SM . UCLA Thrombolysis Investigators. Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. Stroke 2005; 36: 388–97.

Schellinger PD Fiebach JB Hacke W : Imaging-based decision making in thrombolytic therapy for ischemic stroke: Present status. Stroke 2003; 34: 575–83.

Kang DW Chalela JA Dunn W Warach S : MRI screening before standard tissue plasminogen activator therapy is feasible and safe. Stroke 2005; 36: 1939–43.

Kidwell CS Chalela JA Saver JL . Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004; 292: 1823–30.

Fiebach JB Schellinger PD Gass A . Stroke Magnetic Resonance Imaging is accurate in hyperacute intracerebral hemorrhage: A multicentre study on the validity of stroke imaging. Stroke 2004; 35: 502–7.

Albers GW Thijs VN Wechsler L . Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006; 60: 508–17.

Davis SM Donnan GA : Echoplanar Imaging Thrombolysis Evaluation Trial: EPITHET. In International Stroke Conference, Orlando, FL, USA, 2006.

Thomalla G Schwark C Sobesky J . Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6-hours in MRI-selected stroke patients: Comparison of a German multicentre study with the pooled data of ATLANTIS, ECASS, and NINDS tPA Trials. Stroke 2006; 37: 852–8.

Kohrmann M Juttler E Fiebach JB . MRI versus CT-based thrombolysis treatment within and beyond the 3-hour time window after stroke onset: A cohort study. Lancet Neurol 2006; 5: 661–7.

Hacke W Albers G Al-Rawi Y . The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66–73.

Furlan AJ Eyding D Albers GW . Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3–9-hours after stroke onset. Stroke 2006; 37: 1227–31.